neuregulin 1β nrg 1 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
neuregulin 1β nrg 1
Neuregulin 1β Nrg 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 124 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg-1%CE%B2/Recombinant+Human+NRG1-beta+1%2FHRG1-beta+1+EGF+Domain+Protein/pm41437739-32-28-32
Average 95 stars, based on 124 article reviews
Neuregulin 1β Nrg 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 124 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg-1%CE%B2/Recombinant+Human+NRG1-beta+1%2FHRG1-beta+1+EGF+Domain+Protein/pm41437739-32-28-32
Average 95 stars, based on 124 article reviews
neuregulin 1β nrg 1 - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Injection:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Staining:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Recombinant:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Concentration Assay:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Incubation:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Marker:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Expressing:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or RNA Expression:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Western Blot:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Comparison:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Microscopy:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or Generated:Article Title: Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Article Snippet: Trastuzumab (Herceptin), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2 breast cancer patients.. However, the drug also has known cardiotoxic side effects through mechanisms that are not fully understood.. Here we utilized human induced pluripotent stem cellderived cardiomyocytes (iPS-CMs) to model trastuzumab-related cardiotoxicity in vitro. Article Title: Immunotherapy against ErbB-3 receptor Article Snippet: In detail, the recombinant protein HER3-ECD-Fc was bound to Nunc Maxisorp plastic plates over night at the concentration of 1 μg/ml in PBS at 4° C. Anti-HER3 antibodies were then added for 1 hour at 37° C., followed by an incubation for 1 hour with 90 ng/100 μl/well with Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Dynamic Analysis of the Epidermal Growth Factor (EGF) Receptor-ErbB2-ErbB3 Protein Network by Luciferase Fragment Complementation Imaging Article Snippet: Article Title: Spatio-temporal assessment of the neuroprotective effects of neuregulin-1 on ischemic stroke lesions using MRI Article Snippet: NRG-1 administration To determine the effects of NRG-1 on ischemic stroke, rats were randomized and injected intra-arterially with a single bolus 50 μl dose of vehicle (1%BSA in PBS) or Article Title: Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors Article Snippet: Article Title: Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling Article Snippet: For this, hESC-CMs ( ̃5×106 million per well) were treated on day 10 post-induction with 0, 10, or 100 ng/ml Article Title: Chimeric neuregulins and method of making and use thereof Article Snippet: To determine the effects of NRG-1 on ischemic stroke, rat were injected intravascularly with a single bolus 10 μl dose of vehicle (1% BSA in PBS) or |